• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期随访:全身高血压合并视网膜中央静脉阻塞相关性黄斑水肿患者接受多次抗 VEGF 治疗注射后脉络膜中央厚度变薄的变化。

Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.

机构信息

Department of Ophthalmology, Osaka Medical College, Takatsuki, Japan,

Department of Ophthalmology, Osaka Medical College, Takatsuki, Japan.

出版信息

Ophthalmologica. 2020;243(2):102-109. doi: 10.1159/000504754. Epub 2019 Dec 18.

DOI:10.1159/000504754
PMID:31851998
Abstract

PURPOSE

We investigated the thinning of central choroidal thickness (CCT) following intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs to treat central retinal vein occlusion (CRVO)-related macular edema in patients with and without systemic hypertension (HT) to assess the influence of repeated anti-VEGF therapy and HT on the choroid in CRVO eyes.

METHODS

We conducted a retrospective study involving 27 patients with CRVO-related macular edema from January 2014 to July 2017, with follow-ups exceeding 18 months. Visual acuity (VA), central retinal thickness (CRT), and CCT were evaluated before and after initial anti-VEGF drug treatment during follow-up.

RESULTS

The mean follow-up period was 35.2 months. Seventeen (63.0%) patients had HT. At 1 month after treatment, VA had improved in 21 (77.8%) patients, and CRT had decreased in 25 (92.6%). At the final visit, 22 (81.5%) showed improved VA, 19 (70.4%) had resolved macular edema, and the CCT had gradually become thinner with additional drug injections in all the patients. Furthermore, the mean CCT in HT patients (209.0 µm) was significantly lower than in non-HT patients (256.1 µm), and the mean injections were 7.8 and 5.3, respectively (p = 0.2067).

CONCLUSION

The CCTs were thinner in eyes with HT than in eyes without HT both before and after the repeated anti-VEGF injections.

摘要

目的

我们研究了玻璃体内注射抗血管内皮生长因子(anti-VEGF)药物治疗伴有或不伴有系统性高血压(HT)的视网膜中央静脉阻塞(CRVO)相关黄斑水肿患者后中央脉络膜厚度(CCT)的变薄情况,以评估重复抗 VEGF 治疗和 HT 对 CRVO 眼脉络膜的影响。

方法

我们进行了一项回顾性研究,纳入了 2014 年 1 月至 2017 年 7 月期间的 27 例 CRVO 相关黄斑水肿患者,随访时间超过 18 个月。在随访期间,我们评估了初始抗 VEGF 药物治疗前后的视力(VA)、中心视网膜厚度(CRT)和 CCT。

结果

平均随访时间为 35.2 个月。17 例(63.0%)患者患有 HT。治疗后 1 个月,21 例(77.8%)VA 改善,25 例(92.6%)CRT 降低。在最后一次就诊时,22 例(81.5%)VA 改善,19 例(70.4%)黄斑水肿消退,所有患者随着药物注射次数的增加,CCT 逐渐变薄。此外,HT 患者的平均 CCT(209.0 µm)明显低于非 HT 患者(256.1 µm),平均注射次数分别为 7.8 和 5.3(p = 0.2067)。

结论

在重复抗 VEGF 注射前后,HT 眼的 CCT 均比非 HT 眼薄。

相似文献

1
Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.长期随访:全身高血压合并视网膜中央静脉阻塞相关性黄斑水肿患者接受多次抗 VEGF 治疗注射后脉络膜中央厚度变薄的变化。
Ophthalmologica. 2020;243(2):102-109. doi: 10.1159/000504754. Epub 2019 Dec 18.
2
Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.视网膜中央静脉阻塞或半侧视网膜静脉阻塞继发黄斑水肿患者6个月视力和视网膜厚度结果的基线因素:SCORE2研究报告4
JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141.
3
Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.光学相干断层扫描(OCT)引导下贝伐单抗治疗视网膜静脉阻塞所致黄斑水肿的长期随访
Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1635-41. doi: 10.1007/s00417-009-1151-1. Epub 2009 Jul 26.
4
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.与中央视网膜静脉阻塞患者相比,视网膜静脉阻塞 2 期(SCORE2)研究报告 18 中接受抗血管内皮生长因子治疗的半视网膜静脉阻塞患者的基线特征和结局
JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352.
5
EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.阿柏西普与雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的疗效及频率。
Retina. 2018 Sep;38(9):1795-1800. doi: 10.1097/IAE.0000000000001782.
6
Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger.40岁及以下视网膜中央静脉阻塞相关黄斑水肿患者的玻璃体内抗血管内皮生长因子注射治疗
Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):e96-e104. doi: 10.3928/23258160-20190401-13.
7
Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.玻璃体内注射贝伐单抗治疗视网膜分支静脉阻塞后黄斑水肿的疗效,按基线视力分层分析
Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):691-697. doi: 10.1007/s00417-016-3535-3. Epub 2016 Oct 29.
8
Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.前瞻性研究曲安奈德与贝伐单抗治疗视网膜中央静脉阻塞继发黄斑水肿。
Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.
9
Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.重复玻璃体内注射地塞米松治疗视网膜静脉阻塞继发的黄斑囊样水肿(无论是否转换为抗血管内皮生长因子药物)的安全性和长期疗效:一项为期3年的经验
Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1441-1448. doi: 10.1007/s00417-018-4016-7. Epub 2018 May 31.
10
Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.奥扎格雷与抗血管内皮生长因子药物玻璃体腔内注射治疗视网膜静脉阻塞相关性黄斑水肿的比较:一项随机对照试验的系统评价和荟萃分析。
Indian J Ophthalmol. 2019 Nov;67(11):1800-1809. doi: 10.4103/ijo.IJO_382_19.

引用本文的文献

1
Clinical efficacy of conbercept plus micropulse laser (577 nm) treatment in macular edema secondary to non-ischemic central retinal vein occlusion.康柏西普联合微脉冲激光(577nm)治疗非缺血性视网膜中央静脉阻塞继发黄斑水肿的临床疗效
Pak J Med Sci. 2022 May-Jun;38(5):1366-1370. doi: 10.12669/pjms.38.5.5231.
2
Changes in peripapillary and subfoveal choroidal thickness in patients with central retinal vein occlusion.中心性视网膜静脉阻塞患者的视盘周围和黄斑下脉络膜厚度的变化。
PLoS One. 2021 Aug 20;16(8):e0255182. doi: 10.1371/journal.pone.0255182. eCollection 2021.
3
Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy.
长期抗血管内皮生长因子治疗下的厚脉络膜新生血管病变中的脉络膜消失。
BMC Ophthalmol. 2021 Jun 30;21(1):269. doi: 10.1186/s12886-021-02022-1.